Open AccessRapid cycling bipolar disorder: Literature review on pharmacological treatment illustrated by a case report on ketamine
Author(s) -
Bourla Alexis,
Ferreri Florian,
Baudry Thomas,
Panizzi Vincent,
Adrien Vladimir,
Mouchabac Stéphane
Publication year - 2022
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.2483
Subject(s) - mania , hypomania , bipolar disorder , mood , ketamine , psychiatry , medicine , depression (economics) , medline , psychology , political science , law , economics , macroeconomics
Rapid cycling bipolar disorder (RCBD) is defined as four or more affective episodes (depression, mania or hypomania) within 1 year. RCBD has a high point of prevalence (from 10% to 20% among clinical bipolar samples) and is associated with greater severity, longer illness duration, worse global functioning and higher suicidal risk, but there is no consensus on treatment option. The use of several pharmacological agents has been reported (levothyroxine, antipsychotics, antidepressants and mood stabilizers). Objective The main objective of this review was to propose a critical review of the literature and to rank the pharmacological agent using a level of evidence (LEO) adapted from the Center for Evidence‐Based Medicine, and to illustrate it with a case report on off‐label intravenous ketamine. Method We conducted a review using the MeSH terms and keywords (bipolar [Title/Abstract]) AND (rapid [Title/Abstract]) AND (cycling [Title/Abstract]) AND (treatment [Title/Abstract]). Alexis Bourla and Stéphane Mouchabac screened 638 documents identified through literature search in Medline (PubMed) or by bibliographic references and 164 abstracts were then analyzed. Nonpharmacological treatments were excluded. Result Seventy articles were included in the review and divided into six categories: mood stabilizers, antipsychotics, hormonal treatments, ketamine and other pharmacological treatments. Discussion Our review highlights the heterogeneity of the pharmacological treatment of RCBD and no clear consensus can emerge.